[
  {
    "ts": null,
    "headline": "Insulet adds Abbott’s FreeStyle Libre 2 Plus to Omnipod 5’s compatibility roster",
    "summary": "The Omnipod 5, which already connects with Dexcom’s CGMs, now boasts Abbott’s flagship diabetes product.",
    "url": "https://finnhub.io/api/news?id=b12eb2d028cc0c1da7a5049f05e1e476964e13d6b3dfd8514c0a8b76d6f12b3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732195669,
      "headline": "Insulet adds Abbott’s FreeStyle Libre 2 Plus to Omnipod 5’s compatibility roster",
      "id": 131542224,
      "image": "https://www.medicaldevice-network.com/wp-content/uploads/sites/23/2024/11/OMNIPOD_SCENE17_342_RGB.jpg",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "The Omnipod 5, which already connects with Dexcom’s CGMs, now boasts Abbott’s flagship diabetes product.",
      "url": "https://finnhub.io/api/news?id=b12eb2d028cc0c1da7a5049f05e1e476964e13d6b3dfd8514c0a8b76d6f12b3a"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Convertible Securities Fund Q3 2024 Commentary",
    "summary": "Nine out of 11 sector allocations contributed to the fundâs absolute return in 3Q24, while detractors in the communication services and materials sectors had a modest impact.",
    "url": "https://finnhub.io/api/news?id=304bc155138f0106581ec29a8a62b79d6836a2ec34d08e7c09960abf9afb4f50",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732183140,
      "headline": "Franklin Convertible Securities Fund Q3 2024 Commentary",
      "id": 131539355,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2143902525/image_2143902525.jpg?io=getty-c-w1536",
      "related": "PODD",
      "source": "SeekingAlpha",
      "summary": "Nine out of 11 sector allocations contributed to the fundâs absolute return in 3Q24, while detractors in the communication services and materials sectors had a modest impact.",
      "url": "https://finnhub.io/api/news?id=304bc155138f0106581ec29a8a62b79d6836a2ec34d08e7c09960abf9afb4f50"
    }
  },
  {
    "ts": null,
    "headline": "Insulet: Superb Business Growth, Starting Valuations Outsized Risk",
    "summary": "Insulet Corporation trades at exorbitant multiples despite expected growth outcomes. Read why PODD remains a hold on valuations in my view.",
    "url": "https://finnhub.io/api/news?id=c9b5a42dfe8c3ea1ddb1ddb7595426f2d9f59bf829da5f0ff9bc26e778bc7d21",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732175758,
      "headline": "Insulet: Superb Business Growth, Starting Valuations Outsized Risk",
      "id": 131536965,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
      "related": "PODD",
      "source": "SeekingAlpha",
      "summary": "Insulet Corporation trades at exorbitant multiples despite expected growth outcomes. Read why PODD remains a hold on valuations in my view.",
      "url": "https://finnhub.io/api/news?id=c9b5a42dfe8c3ea1ddb1ddb7595426f2d9f59bf829da5f0ff9bc26e778bc7d21"
    }
  }
]